New dog-sized dinosaur identified after fossil mix-up
Incomplete fossil remains of the newly named enigmacursor mollyborthwickae were initially discovered in modern-day Colorado in 2021-22 but were misclassified by scientists as being the remains of a nanosaurus.
In a newly published report, scientists behind the discovery note that the small herbivore was about 3 feet long, with its tail making up about half of its length.
Dinosaurs didn't roar like in the movies. Here's how they sounded
According to the museum, the name enigmacursor roughly translates to 'puzzle runner' in Latin. Despite its small stature, this two-legged dinosaur had long legs, which allowed it to quickly move away from predators.
'We can speculate that Enigmacursor probably wasn't that old, as it doesn't seem to have many of its neural arches fused in place. However, the way the fossil was prepared before it was acquired by the Natural History Museum has obscured some of these details, so we can't be certain,' Paul Barrett, co-lead author, said.
New 2-clawed dinosaur discovered in Mongolia
The remains, which date back to roughly 150 million years ago, are now on display at the Natural History Museum in London, marking the museum's first new dinosaur on display since 2014. Unearthed from the Morrison Formation of the Western United States, the dinosaur is said to have roamed the same region as dinosaurs like the stegosaurus and diplodocus.
'While the Morrison Formation has been well-known for a long time, most of the focus has been on searching for the biggest and most impressive dinosaurs,' professor Susannah Maidment, co-lead author of the report, told the museum. 'Engimacusor shows that there's still plenty to discover in even this well-studied region and highlights just how important it is to not take historic assumptions about dinosaurs at face value.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
2 hours ago
- CNN
On GPS: The Trump administration's war on science
Secretary of Health and Human Services Robert F. Kennedy Jr. announced that he is cutting nearly half a billion dollars in federally funded mRNA vaccine research. Fareed speaks with former Baltimore Health Commissioner Dr. Leana Wen about the promises of mRNA technology for treating infectious diseases and the impact of cuts on America's scientists.
Wall Street Journal
2 hours ago
- Wall Street Journal
Pump the Brakes on E-Bikes
I applaud the efforts in New York City to adopt an e-bike speed limit of 15 miles per hour, paralleling safety actions abroad ('New York Has a New E-Bike Speed Limit—and Can't Enforce It,' Page One, Aug. 8). Scientific literature from Europe, Asia and the Middle East documents the severe neurosurgical, orthopedic, maxillofacial and other traumatic injuries associated with the higher rate of speed for e-bikes compared to traditional pedal bicycles. The U.S. should learn from this experience and spare the public repeated tragedies. New York can continue to lead the way by implementing new requirements for licensure and registration for those e-bikes that travel at higher speeds more closely resembling mopeds and motorcycles. This will enable law enforcement to identify these vehicles in traffic flow and restrict their use to the roadway instead of bike lanes and sidewalks, where they are more likely to collide with pedestrians in densely populated areas.
Yahoo
3 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
